Kamink SS, Collin SM, Harrison TS, Gatluak F, Mullahzada AW, et al.
2017-10-02 • PLOS Neglected Tropical Diseases
2017-10-02 • PLOS Neglected Tropical Diseases
BACKGROUND South Sudan is one of the most endemic countries for visceral leishmaniasis (VL), and is frequently affected by large epidemics. In resource-limited settings, clinicians r...
Ritmeijer KKD, ter Horst R, Chane S, Aderie EM, Piening T, et al.
2011-10-19 • Clinical Infectious Diseases
2011-10-19 • Clinical Infectious Diseases
Due to unacceptably high mortality with pentavalent antimonials, Médecins Sans Frontières in 2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients...
Naylor-Leyland G, Collin SM, Gatluak F, den Boer ML, Alves F, et al.
2022-08-18 • PLOS Neglected Tropical Diseases
2022-08-18 • PLOS Neglected Tropical Diseases
BACKGROUND Visceral Leishmaniasis (VL) is endemic in South Sudan, manifesting periodically in major outbreaks. Provision of treatment during endemic periods and as an emergency respo...
BACKGROUND: Risk factors associated with L. donovani visceral leishmaniasis (VL; kala azar) relapse are poorly characterized. METHODS: We investigated patient characteristics and drug re...
Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer KKD, et al.
2007-07-01 • American Journal of Tropical Medicine and Hygiene
2007-07-01 • American Journal of Tropical Medicine and Hygiene
Médecins sans Frontières-Holland has treated > 67,000 patients with kala-azar (KA) in southern Sudan since 1989. In 2002, we replaced the standard regimen of 30 days of daily sodium stib...
